Arash Salardini, MD
Neurology · San Antonio, TXNPI 1073749776
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $102,260 of the $124,661 with a category attached, or 82.0%. Lilly USA, LLC accounts for 88.0% of it on its own, with 5 other manufacturers making up the rest. 2025 is the largest year on record at $82,648, more than ten times the $914 reported in 2019. Among neurology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 112 payments — averaging $1113.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$110K
- Biogen$15K
- Alnylam Pharmaceuticals Inc.$125
- Penumbra, Inc.$120
- Johnson & Johnson$114
- Eisai Inc.$85
Across 20 payments — averaging $13,886 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eisai Inc.$164K
- Biogen$114K
What the payments were for
- Consulting fees$8001%
- Speaking & faculty fees$102,26082%
- Travel & lodging$18,56815%
- Food & beverage$3,0322%
- Education$10%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 99 | $109,643 |
| Biogen | 9 | $14,573 |
| Alnylam Pharmaceuticals Inc. | 1 | $125 |
| Penumbra, Inc. | 1 | $120 |
| Johnson & Johnson | 1 | $114 |
| Eisai Inc. | 1 | $85 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KISUNLA$91,132
- AMVUTTRA$125
- Indigo System$120
- XARELTO$114
How this compares
$124,661 in reported general payments places this provider in the 95th percentile of 1,246 neurology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 13 | $54,085 |
| Rivastigmine | 23 | $9,088 |
| Memantine Hcl | 200 | $7,236 |
| Donepezil Hcl | 326 | $3,065 |
| Memantine Hcl ErMemantine Hcl | 14 | $1,441 |
| Escitalopram Oxalate | 184 | $1,178 |
| Quetiapine Fumarate | 61 | $939 |
| Divalproex Sodium | 16 | $435 |
| Mirtazapine | 23 | $415 |
| Divalproex Sodium ErDivalproex Sodium | 15 | $360 |
| Fluoxetine Hcl | 19 | $290 |
| Sertraline Hcl | 22 | $235 |
| Trazodone Hcl | 39 | $91 |
Paid to pharmacies, not to this prescriber.
Other neurology in San Antonio
- Ann BassSan Antonio$1.7M
- Santiago RestrepoSan Antonio$532K
- Juan Ramirez CastanedaSan Antonio$456K
- Eleni VaouSan Antonio$236K
- Eric PappertSan Antonio$166K
- William OndoHouston$1.4M
- Nirav PavasiaDallas$1.4M
- Mirla AvilaLubbock$1.3M
- Michael SoileauGeorgetown$1.2M
- Pankaj SatijaHouston$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.